View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 27, 2020updated 12 Jul 2022 11:48am

Boehringer and Lilly study Jardiance in EMPACT-MI heart failure trial

Boehringer Ingelheim and Eli Lilly have partnered with the Duke Clinical Research Institute (DCRI) to conduct an EMPACT-MI clinical trial of Jardiance (empagliflozin) to prevent heart failure.

Boehringer Ingelheim and Eli Lilly have partnered with the Duke Clinical Research Institute (DCRI) to conduct an EMPACT-MI clinical trial of Jardiance (empagliflozin) to prevent heart failure.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The study will assess the drug’s ability to improve outcomes and prevent heart failure in adults with or without diabetes who have experienced acute myocardial infarction or heart attack.

DCRI will work with the companies to conduct, analyse and report the trial, while Boehringer and Lilly provide funding.

Jardiance is a prescription drug indicated for use with diet and exercise to lower blood sugar in adults with type 2 diabetes. It is also used to decrease the risk of cardiovascular death in type 2 diabetes patients who have known cardiovascular disease.

The randomised, blinded, placebo-controlled, multi-centre trial will assess the safety and efficacy in adults hospitalised with an acute myocardial infarction. It will enrol about 3,300 patients in at least 16 countries.

EMPACT-MI is part of the EMPOWER programme, a large-scale clinical trial scheme evaluating Jardiance in patients with cardio-renal-metabolic conditions.

Eli Lilly Product Development vice-president Jeff Emmick said: “The EMPACT-MI trial is part of our broad and comprehensive clinical development programme, which aims to explore how Jardiance can improve health outcomes and fill therapeutic gaps for a broad range of patients suffering from cardio-renal-metabolic conditions.”

The primary endpoint of the EMPACT-MI trial is the effect of the drug on all-cause mortality and hospitalisation for heart failure. EMPACT-MI is a pragmatic trial, which focus on the link between therapies and outcomes in a real-world setting.

DCRI will contribute via its experience in pragmatic trials. It will deploy new trial elements, including remote follow-up and a focused data collection method.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena